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Objective:  This  study  aimed  at  evaluating  the  predictors  and  outcomes  associated  with
multidrug-resistant  gram-negative  bacterial  (MDR-GNB)  infections  in  an  oncology  pediatric
intensive  care  unit  (PICU).
Methods:  Data  were  collected  relating  to  all  episodes  of  GNB  infection  that  occurred  in  a
PICU between  January  of  2009  and  December  of  2012.  GNB  infections  were  divided  into  two
groups for  comparison:  (1)  infections  attributed  to  MDR-GNB  and  (2)  infections  attributed  to
non-MDR-GNB.  Variables  of  interest  included  age,  gender,  presence  of  solid  tumor  or  hemato-
logic disease,  cancer  status,  central  venous  catheter  use,  previous  Pseudomonas  aeruginosa
infection, healthcare-associated  infection,  neutropenia  in  the  preceding  7  days,  duration  of
neutropenia,  length  of  hospital  stay  before  ICU  admission,  length  of  ICU  stay,  and  the  use  of
any of  the  following  in  the  previous  30  days:  antimicrobial  agents,  corticosteroids,  chemother-
apy, or  radiation  therapy.  Other  variables  included  initial  appropriate  antimicrobial  treatment,
deﬁnitive  inadequate  antimicrobial  treatment,  duration  of  appropriate  antibiotic  use,  time  to
initiate adequate  antibiotic  therapy,  and  the  7-  and  30-day  mortality.
Results:  Multivariate  logistic  regression  analyses  showed  signiﬁcant  relationships  between
MDR-GNB  and  hematologic  diseases  (odds  ratio  [OR]  5.262;  95%  conﬁdence  interval  [95%  CI]
1.282--21.594;  p  =  0.021)  and  healthcare-associated  infection  (OR  18.360;  95%  CI  1.778--189.560;
p =  0.015).  There  were  signiﬁcant  differences  between  MDR-GNB  and  non-MDR-GNB  patients
for the  following  variables:  inadequate  initial  empirical  antibiotic  therapy,  time  to  initiate
adequate  antibiotic  treatment,  and  inappropriate  antibiotic  therapy.
Conclusions:  Hematologic  malignancy  and  healthcare-associated  infection  were  signiﬁcantly
associated  with  MDR-GNB  infection  in  this  sample  of  pediatric  oncology  patients.
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Resultado
Infecc¸ão  por  bactérias  gram-negativas  multirresistentes  em  uma  unidade  de  terapia
intensiva  pediátrica  oncológica:  fatores  de  risco  e  resultados
Resumo
Objetivo:  Este  estudo  visou  avaliar  os  preditores  e  resultados  associados  às  infecc¸ões  por
bactérias  gram-negativas  multirresistentes  (BGN-MR)  em  uma  unidade  de  terapia  intensiva
pediátrica oncológica  (UTIP).
Métodos:  Foram  coletados  dados  com  relac¸ão  a  todos  os  episódios  de  infecc¸ão  por  BGN  que
ocorreram  em  uma  UTIP  entre  janeiro  de  2009  e  dezembro  de  2012.  As  infecc¸ões  por  BGN  foram
divididas em  dois  grupos  para  comparac¸ão:  1)  infecc¸ões  atribuídas  a  BGN-MR  e  2)  infecc¸ões
atribuídas  a  BGN  não  multirresistente.  As  variáveis  de  interesse  incluíram  idade,  sexo,  presenc¸a
de tumor  sólido  ou  malignidade  hematológica,  câncer,  uso  de  cateter  venoso  central,  infecc¸ão
anterior por  Pseudomonas  aeruginosa,  infecc¸ão  hospitalar,  neutropenia  nos  7  dias  anteriores,
durac¸ão da  neutropenia,  tempo  de  internac¸ão  antes  da  UTI,  durac¸ão  da  internac¸ão  na  UTI  e  uso
de quaisquer  dos  seguintes  nos  30  dias  anteriores:  agentes  antimicrobianos,  corticosteroides,
quimioterapia  ou  radioterapia.  Outras  variáveis  incluíram:  tratamento  antimicrobiano  inicial
adequado,  tratamento  antimicrobiano  deﬁnitivo  inadequado,  durac¸ão  do  uso  de  antibióticos
adequados,  tempo  de  início  da  terapia  antibiótica  adequada,  mortalidade  em  7  dias  e  mortali-
dade em  30  dias.
Resultados:  As  análises  de  regressão  logística  multivariada  mostraram  relac¸ões  signiﬁcativas
entre as  BGN-MR  e  as  doenc¸as  hematológicas  (razão  de  chance  (RC)  5,262;  intervalo  de  conﬁanc¸a
de 95%  (IC  de  95%)  1,282--21,594;  p  =  0,021)  e  infecc¸ões  hospitalares  (RC  18,360;  IC  de  95%
1,778--189,560;  p  =  0,015).  Houve  diferenc¸as  signiﬁcativas  entre  os  pacientes  com  BGN-MR  e
BGN não  MR  com  relac¸ão  às  seguintes  variáveis:  recebimento  de  terapia  antibiótica  empírica
inicial inadequada,  tempo  para  início  do  tratamento  antibiótico  adequado  e  recebimento  de
terapia antibiótica  inadequada.
Conclusões:  A  malignidade  hematológica  e  a  infecc¸ão  hospitalar  foram  signiﬁcativamente  asso-
ciadas à  infecc¸ão  por  BGN-MR  nessa  amostra  de  pacientes  pediátricos  oncológicos.














































atients  with  cancer  and  hematologic  malignancy  are  at
igh  risk  of  infections.  A  number  of  factors  contribute  to
his  risk,  including  immunosuppression  related  to  the  dis-
ase  and  aggressive  treatments,  such  as  chemotherapy,
adiation  therapy,  steroid  use,  and  hematopoietic  stem  cell
ransplantation.1 As  a  result,  infection  remains  a  frequent
omplication  in  patients  with  cancer  and  is  responsible  for
ntensive  care  unit  (ICU)  admissions.1 However,  with  recent
dvances  in  cancer  treatments  and  improvements  in  criti-
al  care,  an  increasing  number  of  patients  with  hematologic
alignancies  are  being  admitted  to  the  ICU.2 Despite  the
mprovements  in  outcomes  associated  with  improved  care,
ortality  remains  high  in  critically  ill  patients  with  cancer
r  hematologic  malignancies,  particularly  in  the  presence  of
CU-acquired  nosocomial  infections.2
Speciﬁcally,  the  rate  of  infections  related  to  multidrug-
esistant  gram-negative  bacteria  (MDR-GNB)  in  patients
ith  cancer  is  increasing  globally.3 However,  treatment
ptions  for  MDR-GNB  infections  are  often  limited.  Car-
apenems  are  the  drugs  of  choice  for  infections  caused  by
xtended-spectrum  -lactamase  (ESBL)-producing  microor-
anisms,  but  their  use  may  not  be  appropriate  in  infections
aused  by  Pseudomonas  aeruginosa, Acinetobacter  bauman-




eo  carbapenems  is  increasing.  There  are  very  few  new
ntimicrobial  agents  available  for  the  treatment  of  MDR-
NB.4 Owing  to  the  lack  of  novel  agents  to  treat
esistant  infections,  clinicians  must  use  antibiotics  judi-
iously  and  appropriately  to  limit  the  development  of
esistance.5
The  presence  of  cancer,  hematologic  malignancy,  and
 prior  or  current  ICU  stay  increases  the  risk  of  mortality
n  patients  with  infections  due  to  MDR-GNB.6 In  addition,
NB  infection  is  associated  with  MDR  in  febrile  neutropenic
ediatric  cancer  patients.7 Previous  studies  have  provided
nformation  about  the  risk  factors  for  colonization  or  infec-
ion  with  MDR-GNB  in  select  patient  populations,  such  as
ransplant  patients  and  those  in  intensive  or  long-term
are.8,9 Studies  involving  cancer  patients  have  focused  on
loodstream  infections.  Limited  information  is  available
egarding  the  spectrum  and  microbiology  of  these  infections
n  other  sites,  such  as  the  urinary  tract,  respiratory  tract,
astrointestinal  tract,  and  skin.  This  is  despite  the  fact  that
uch  infections  are  not  rare.10
Little  is  known,  in  particular,  regarding  the  risk  factors
nd  outcomes  of  MDR-GNB  infections  in  an  oncology  pedi-
tric  ICU  (PICU).  Therefore,  this  study  aimed  at  evaluating
he  risk  factors  and  outcomes  associated  with  MDR-GNB





















































pMultidrug-resistant  gram-negative  infection  
Materials and methods
Study  design
A  case--control  study  was  performed  in  the  National  Can-
cer  Institute  (Instituto  Nacional  do  Câncer  [INCA])  PICU,  Rio
de  Janeiro,  Brazil.  INCA  is  a  tertiary  oncology  public  hospi-
tal,  and  the  six-bed  PICU  admits  only  patients  with  solid
tumors  and  hematologic  malignancies.  The  principal  rea-
sons  for  admission  to  the  PICU  are  postoperative  care  and
infectious  complications  in  oncology  patients.
Data  were  collected  from  all  infection  episodes  related  to
GNB  that  occurred  between  January  1,  2009  and  December
31,  2012  in  PICU  patients,  aged  between  0  months  and  18
years,  who  were  hospitalized  for  more  than  24  h.  The  Ethics
Committee  of  Fluminense  Federal  University  approved  the
study.
Variables  included  age,  gender,  the  presence  of  a  solid
tumor  or  hematologic  malignancy,  cancer  status,  and  the
presence  of  a  central  venous  catheter.  Information  prior
to  the  date  of  GNB  infection  was  also  collected:  previous
infection  related  to  P.  aeruginosa, neutropenia  in  the  pre-
ceding  7  days,  length  of  neutropenia  ≥3  days,  duration  of
ICU  stay  >3  days,  length  of  hospitalization  before  ICU  admis-
sion,  and  healthcare-associated  infection,  in  addition  to  the
use  of  antimicrobial  agents,  corticosteroids,  and  chemother-
apy  and/or  radiation  therapy  in  the  previous  30  days.
Infections  caused  by  GNB  were  divided  into  2  groups:
(1)  infections  attributed  to  MDR-GNB  and  (2)  infections
attributed  to  susceptible  GNB  (non-MDR-GNB).  The  groups
were  similar  with  respect  to  the  infection  site.  Patients
were  included  more  than  once  in  the  analysis  for  separate
episodes  of  infection.  Others  variables  included:  appropri-
ate  initial  antimicrobial  treatment,  deﬁnitive  inadequate
antimicrobial  treatment,  duration  of  appropriate  antibiotic
use,  length  of  time  to  initiate  adequate  antibiotic  therapy,
7-day  mortality,  and  30-day  mortality.
Deﬁnition  of  terms
An  episode  of  infection  was  deﬁned  as  the  isolation  of  GNB
in  the  presence  of  compatible  clinical  signs  or  symptoms
from  3  days  before  the  date  of  PICU  admission  to  the  last
day  of  hospitalization  in  the  PICU.  Healthcare-associated
infections  and  those  present  on  admission  were  included.
The  diagnostic  criteria  of  the  Centers  for  Disease  Control
and  Prevention  were  used.  GNB  were  isolated  from  cultures
of  the  blood,  urine,  stool,  bronchoalveolar  lavage,  tracheal
aspirate,  liquor,  or  catheter  tip  during  this  time.  The  tra-
cheal  aspirate  was  collected  from  endotracheal  tubes  and
the  tracheostomy  of  patients  who  underwent  mechanical
ventilation.
The  diagnostic  criteria  for  pneumonia  included  puru-
lent  tracheobronchial  secretion  or  new  pathogenic  bacteria
isolated  from  tracheal  aspirate  and  at  least  two  of  the
following  criteria:  fever  (temperature  >38 ◦C);  leukocytes
>12,000  cells/mL  or  <4000  cells/mL  increase;  a  new  and  per-
sistent  (>48  h)  inﬁltrate  detected  on  a  chest  radiograph;  new
onset  or  worsening  cough  or  dyspnea  or  tachypnea;  or  wors-




sed  in  the  pneumonia  criteria  were  ≥104 CFU/mL  in  tra-
heal  aspirate  or  bronchoalveolar  lavage.
Catheter  cultures  were  performed  when  a  catheter  was
emoved  for  suspected  intravascular  catheter-related  infec-
ion,  unexplained  sepsis  or  erythema  overlying  the  catheter
nsertion  site,  or  purulence  at  the  catheter  insertion  site.  At
east  one  of  the  following  signs  or  symptoms  was  required
or  the  diagnosis  of  catheter-associated  infection:  fever
>38 ◦C),  pain,  erythema,  heat  at  the  vascular  site  with  no
ther  recognized  cause  and  >15  colonies  cultured  from  an
ntravascular  cannula  tip  using  a  semiquantitative  culture
ethod,  and  lack  of  a  blood  culture  or  no  organisms  cultured
rom  blood.
The  diagnostic  criteria  for  urinary  tract  infection
ncluded  a positive  urine  culture  of  ≥105 CFU/mL  and
ith  no  more  than  two  species  of  microorganisms,  and  at
east  one  of  following  signs  or  symptoms  was  required  for
iagnosis:  fever  (>38 ◦C);  dysuria;  suprapubic  tenderness;
ostovertebral  angle  pain  or  tenderness  with  no  other  rec-
gnized  cause.
The  diagnostic  criteria  for  gastroenteritis  included  acute
nset  of  diarrhea  (liquid  stools  for  >12  h)  with  or  with-
ut  vomiting  or  fever  (>38 ◦C),  no  likely  non-infectious
ause  (e.g.,  diagnostic  tests,  therapeutic  regimen  other
han  antimicrobial  agents,  acute  exacerbation  of  a  chronic
ondition,  or  psychological  stress),  and  an  enteric  pathogen
etected  in  a  stool  culture.
MDR-GNB  infection  was  considered  in  the  presence  of
SBL-producing  Enterobacteriaceae, microorganisms  with
ntrinsic  resistance  mechanisms  such  as  S.  maltophilia  and
lizabethkingia  meningoseptica,  or  carbapenem-resistant
NB.  Carbapenem-resistant  P.  aeruginosa  and  A.  bau-
annii  were  considered  MDR-GNB.  Polymicrobial  infection
nvolved  the  isolation  of  more  than  one  pathogen  from
 culture  sample.  Infection  was  classiﬁed  as  healthcare
cquired  when  onset  occurred  >48  h  after  admission  to  the
tudy  hospital  (ward  or  PICU).  Neutropenia  was  deﬁned
s  an  absolute  neutrophil  count  <500/mm3 in  the  blood
ample.
Hematologic  malignancy  included  leukemias  and  lym-
homa.  Cancer  status  was  classiﬁed  into  three  categories:
emission/controlled  (patients  in  cancer  remission  or
ontrol  who  had  undergone  previous  treatments,  with-
ut  evidence  of  recurrence  according  to  the  attending
ncologist/hematologist),  recent  diagnosis  (patients  with
ctive  disease  diagnosed  within  the  previous  three
onths  with  need  for  ﬁrst-line  anticancer  treatment),
nd  relapse/recurrence  (patients  with  active  disease  with
elapse  or  recurrence).
Initial  antimicrobial  treatment  was  considered  inappro-
riate  if  the  initial  treatment  regimen  did  not  include
t  least  one  antibiotic  active  against  the  microorganism
n  vitro  and  when  the  antibiotic  treatment  did  not  com-
ence  on  the  date  of  the  positive  culture.  In  patients  with
SBL-producing  bacteria  cultures,  treatment  with  penicillin
nd  cephalosporin  was  considered  inappropriate.  Deﬁni-
ive  inadequate  antimicrobial  treatment  occurred  when  the
atient  did  not  receive  any  antibiotic  active  against  the
icroorganism  in  vitro  during  the  period  of  hospitalization.
Death  within  7  days  or  30  days  after  the  date  of  the  pos-







































































































acterial  classiﬁcation  was  performed  by  the  INCA  micro-
iology  laboratory  using  the  Vitek  automated  method
Bio-Merieux  Inc.,  Marcy  l’Etoile,  France)  and  manually  con-
rmed  for  bacterial  isolate  identiﬁcation  and  antimicrobial
esistance,  as  per  the  Clinical  Laboratory  Standard  Institute
CLSI)  standards.
tatistical  analysis
tatistical  analysis  was  conducted  using  SPSS  v.17  (SPSS
nc.,  Chicago,  Illinois,  USA).  A  value  of  p  <  0.05  was  con-
idered  statistically  signiﬁcant.  Continuous  variables  were
resented  as  medians,  and  comparative  analysis  was  con-
ucted  using  independent  t-tests.  Chi-squared  and  Fisher’s
xact  tests  were  used  to  compare  categorical  variables,  and
dds  ratios  (OR)  with  95%  conﬁdence  intervals  (95%  CI)  were
alculated.  Univariate  logistic  regression  analyses  identi-
ed  statistically  signiﬁcant  variables  (p  <  0.05)  related  to
DR-GNB  infection  for  inclusion  in  the  multivariate  logistic
egression  analysis,  which  was  performed  using  a  stepwise
odel.
esults
here  were  765  admissions  to  the  PICU  between  January  1,
009  and  December  31,  2012.  There  were  101  episodes  of
NB  infection  in  76  patients  in  86  admissions,  and  47  (46.5%)
f  these  episodes  were  related  to  MDR-GNB  infection.
The  most  frequently  occurring  pathogens  among  the
DR-GNB  were  as  follows:  A.  baumannii, seven  (17%);  S.
altophilia,  seven  (15%);  Enterobacter  spp.,  seven  (15%);
nd  Klebsiella  pneumoniae, seven  (15%).  The  most  fre-
uently  occurring  pathogens  among  the  non-MDR-GNB  were
s  follows:  P.  aeruginosa, 22  (41%);  A.  baumannii, 14  (26%);
nd  K.  pneumoniae, eight  (15%).  Polymicrobial  infection  was
resent  in  one  MDR-GNB  patient  (2.0%,  n  =  1/47)  and  two
on-MDR-GNB  patients  (3.8%,  n  =  2/54).
Among  the  GNB  infection  episodes,  MDR  was  found  at  the
ollowing  frequencies  for  each  of  the  bacterial  strains:  100%
n  =  2/2)  of  Morganella  morganii,  100%  (n  = 1/1)  of  Citrobac-
er  spp.,  87.5%  (n  =  7/8)  of  Enterobacter  spp.,  50%  (n  =  5/10)
f  Escherichia  coli, 46.6%  (n  =  7/15)  of  K.  pneumoniae, 36.4%
n  =  8/22)  of  A.  baumannii, 18.5%  (n  =  5/27)  of  P.  aerugin-
sa,  and  0%  (n  =  0/2)  of  Proteus  mirabilis.  There  were  seven
pisodes  of  infection  by  S.  maltophilia  and  four  episodes
f  infection  by  E.  meningoseptica,  which  are  microorgan-
sms  with  intrinsic  resistance  mechanisms.  There  were  three
pisodes  of  polymicrobial  infection:  one  of  K.  pneumoniae
nd  non-MDR-GNB  E.  coli, one  of  Klebsiella  oxytoca  and
on-MDR-GNB  E.  coli, and  one  of  MDR  P.  aeruginosa  and  S.
altophilia.
In  the  MDR-GNB  group,  bacteria  were  most  frequently
solated  from  the  tracheal  aspirate  (n  =  17,  36.2%),  followed
y  blood  culture  (n  =  8,  17%),  urine  culture  (n  =  4,  8.5%),
nd  catheter  tip  culture  (n  =  3,  6.4%).  In  the  non-MDR-GNB
roup,  bacteria  were  most  frequently  isolated  from  the  tra-
heal  aspirate  (n  =  22,  40.7%),  urine  culture  (n  =  10,  18.5%),
lood  culture  (n  =  10,  18.5%),  and  a  combination  of  blood
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oncordance  between  isolate  microorganisms,  when  GNB
ere  isolated  from  a  combination  of  different  culture.  63.8%
30/47)  of  the  MDR-GNB  group  and  70.3%  (38/54)  of  the
on-MDR-GNB  group  were  mechanically  ventilated  patients.
The  most  frequent  diseases  in  the  group  with  MDR-
NB  infection  were  central  nervous  system  tumor  (19%),
euroblastoma  (15%),  non-Hodgkin  lymphoma  (15%),  and
cute  lymphoblastic  leukemia  (15%).  In  the  group  with  non-
DR-GNB,  the  most  frequent  diseases  were  central  nervous
ystem  tumor  (52%),  neuroblastoma  (11%),  rhabdomyosar-
oma  (6%),  and  Wilms  tumor  (6%).  Only  one  patient  in  the
tudy  group  had  undergone  a  bone  marrow  transplant.
Demographic  and  clinical  characteristics  are  provided  in
able  1.
The  median  neutropenia  duration  was  0  days  in  both
roups  (MDR-GNB  infection,  range  0--36;  non-MDR-GNB
nfection,  range  0--6;  OR  3.747;  95%  CI  1.222--11.488;
 = 0.021).  The  median  of  length  of  ICU  stay  was  8  days
0--80)  in  the  group  with  MDR-GNB  infection  and  2  days
0--45)  in  the  non-MDR-GNB  infection  group  (OR  2.296;  95%
I  0.001--0.015;  p  =  0.024).
The  results  of  the  univariate  logistic  regression  are
escribed  in  Table  1.  In  the  multivariate  logistic  regression
nalysis,  the  presence  of  hematologic  diseases  (OR  5.262;
5%  CI  1.282--21.594;  p  =  0.021)  and  healthcare-associated
nfection  (OR  18.360;  95%  CI  1.778--189.560;  p  =  0.015)  were
igniﬁcantly  associated  with  MDR-GNB  infection  (Table  2).
The  others  variables  associated  with  MDR-GNB  infection
re  detailed  in  Table  3.  Patients  with  an  MDR-GNB  infec-
ion  more  frequently  received  inadequate  initial  empirical
ntibiotic  therapy  (74.5%)  than  those  in  the  non-MDR-GNB
roup  (37.0%,  p  <  0.001),  and  the  time  to  initiate  ade-
uate  antibiotic  therapy  was  longer  for  the  MDR-GNB  group
median:  2  days)  than  for  the  non-MDR-GNB  group  (median:
 days,  p  <  0.001).  The  MDR-GNB  group  was  also  signiﬁcantly
ore  likely  to  receive  deﬁnitive  inappropriate  antibiotic
herapy  (10.6%  vs.  0%,  p  =  0.014).
iscussion
here  is  a  lack  of  studies  with  pediatric  oncology  patients
ospitalized  in  the  ICU  and  with  MDR-GNB  infection.
ematologic  malignancy  and  healthcare-associated  infec-
ion  emerged  as  important  factors  associated  with  MDR-GNB
nfection  in  this  study.
Sepsis  increases  mortality  in  children  with  multiple  organ
ysfunction  syndrome.11 There  are  wide  regional  variations
n  the  incidence  of  each  resistant  pathogen,  and  these
pidemiologic  factors  must  be  considered  when  making
ecisions  about  empiric  antibiotics.5
Recent  studies  have  reported  high  rates  of  MDR-GNB
nfection  in  the  PICU  or  pediatric  oncology  patients.  In
hildren  with  hematological  malignancies  and  febrile  neu-
ropenia,  51.6%  of  bacteremia  episodes  by  K.  pneumonia
ere  resistant  to  ceftazidime.12 Moreover,  in  another  study
n  pediatric  oncology  patients  with  febrile  neutropenia,
0%  of  Acinetobacter  spp.,  44.4%  of  E.  coli, 66.7%  of
.  pneumoniae, and  100%  of  P.  aeruginosa  were  MDR.7
DR  cases  were  present  in  57.1%  of  oncology  pediatric
atients  with  P.  aeruginosa  bacteremia13 and  in  31.4%  of
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Table  1  Demographic  and  clinical  variables  relating  to  multidrug-resistant  gram-negative  bacterial  (MDR-GNB)  infection  in  a
pediatric intensive  care  unit  (PICU),  analyzed  using  univariate  logistic  regression.
MDR-GNB
n  =  47
n  (%)
Non-MDR-GNB
n  =  54
n  (%)
OR  95%  CI  p-Value
Male,  gender  25  (53.2%)  27  (50.0%)  1.360  0.519--2.486  0.749
Age (years)a 7  (0.2--18)  6.5  (2--17)  0.650  0.948--1.089  0.650
Hematologic  disease 18  (38.3%) 6  (11.1%)  4.966  1.768--13.944  0.002
Cancer status  (controlled/remission) 7  (14.9%) 13  (24.1%) 0.552  0.200--1.526  0.252
Central venous  catheter 45  (95.7%) 48  (88.9%) 2.812 0.540--14.662 0.220
Neutropeniab 34  (72.3%) 40  (74.1%) 1.092 0.452--2.640 0.844
Duration  of  neutropenia  ≥3  days  13  (27.7%)  5  (9.3%)  3.747  1.22--11.488  0.021
Previous antibiotic  therapyc 46  (97.9%)  43  (79.6%)  11.760  1.457--95.035  0.021
Healthcare-associated  infection
(from  ward  and  PICU)
46  (97.9%)  36  (66.6%)  23.000  2.930--180.523  0.003
Use of  corticosteroidsc 42  (89.4%)  50  (92.6%)  0.672  0.170--2.664  0.572
Length of  stay  before  ICUa 3  (0--89)  1  (0--56)  1.006  0.978--1.034  0.679
Length of  ICU  stay  >3  days  30  (63.8%)  20  (37%)  3.000  1.332--6.756  0.008
Chemotherapy/radiation  therapyc 33  (70.2%)  39  (72.2%)  0.907  0.382--2.150  0.824
Previous episode  of  Pseudomonas
aeruginosa  infection
7  (14.9%)  10  (18.5%)  0.770  0.268--2.215  0.628
CI, conﬁdence interval; OR, odds ratio; ICU, intensive care unit.
a Reported as median (range).
b In the 7 days prior to the positive culture for gram-negative bacteria.
c In the 30 days prior to the positive culture for gram-negative bacteria.
Table  2  Results  of  the  multivariate  logistic  regression  analysis  for  the  outcome  of  multidrug-resistant  gram-negative  bacteria
(MDR-GNB), including  the  variables  that  were  statistically  signiﬁcant  in  the  univariate  logistic  regression  analysis.
MDR-GNB
n  =  47
n  (%)
Non-MDR-GNB
n  =  54
n  (%)
OR  95%  CI  p-Value
Healthcare-associated
infection
46  (97.9%)  36  (66.6%)  18.360  1.778--189.560  0.015
Hematologic  diseases 18  (38.3%)  6  (11.1%)  5.262  1.282--21.594  0.021
Length of  neutropenia  ≥3  days  13  (27.7%)  5  (9.3%)  2.802  0.602--13.035  0.189
Length of  ICU  stay  >3  days 30  (63.8%)  20  (37%)  1.680  0.613--4.606  0.313
Previous antibiotic  therapya 46  (97.9%)  43  (79.6%)  3.082  0.296--32.049  0.346
CI, conﬁdence interval; OR, odds ratio.
a In the 30 days prior to the positive culture for gram-negative bacteria.
Table  3  Outcomes  and  others  variables  associated  with  the  presence  of  multidrug-resistant  gram-negative  bacteria  (MDR-GNB)
in patients  in  a  pediatric  intensive  care  unit.
MDR-GNB
n  =  47
n  (%)
Non-MDR-GNB
n  =  54
n  (%)
p-Value
Appropriate  initial  antibiotic  treatment  12  (25.5%)  34  (63.0%)  <0.001
Deﬁnitive inadequate  antimicrobial  treatment  5  (10.6%)  0  (0%)  0.014
Length of  time  to  initiate  adequate  antibiotic  therapy  (days)a 2  (0--10)  0  (0--7)  <0.001
Duration of  appropriate  antibiotic  use  (days)a 10.5  (5--22)  10  (2--23)  0.608
7-day mortality  5  (10.6%)  3  (5.6%)  0.345










































































































.  aeruginosa  bacteremia  in  children  undergoing  chemother-
py  and  hematopoietic  stem  cell  transplantation.14
In  the  PICU,  30%  of  K.  pneumonia15 and  23%  of
nterobacteriaceae16 were  ESBL-producing  strains.  Car-
apenem  resistance  in  pediatric  patients  in  the  ICU  is  also
ommon,  with  resistance  observed  in  62%  of  A.  baumannii.17
In  the  present  study,  MDR  was  detected  in  50.0%  of  E.  coli,
6.6%  of  K.  pneumoniae, 36.4%  of  A.  baumannii, and  18.5%
f  P.  aeruginosa.
Recent  studies  in  neutropenic  children  with  cancer  in  dif-
erent  time  periods  have  indicated  an  increase  in  the  rate
f  infections  related  to  A.  baumannii.7 MDR  A.  baumannii
re  now  considered  one  of  the  most  challenging  pathogens
n  critically  ill  patients,7 especially  pediatric  patients,  due
o  the  absence  of  new  effective  antimicrobial  agents.  In  the
resent  study,  A.  baumannii  accounted  for  21.8%  (22/101)  of
ll  episodes  of  infection  with  GNB  and  were  the  most  com-
on  MDR  bacteria  (17%,  8/47),  conﬁrming  the  importance
f  this  etiologic  agent  in  this  population.
In  this  study,  the  most  common  types  of  infection  in  order
f  frequency  were  pneumonia,  bloodstream  infections,  and
rinary  tract  infections.  Other  studies  have  demonstrated
hat  the  main  sites  of  healthcare-associated  infections  in
ICU  are  pneumonia  and  bloodstream  infection.18,19 Onco-
ogic  patients,  when  subjected  to  invasive  procedures  such
s  mechanical  ventilation,  are  more  susceptible  to  infec-
ious  complications  than  the  general  population.
In  patients  with  solid  tumor,  the  primary  treatment
s  often  surgical.  However,  patients  with  hematological
alignancy  often  receive  more  aggressive  chemotherapy,
esulting  in  longer  periods  of  neutropenia,  more  febrile
eutropenia  episodes,  and  more  frequent  antibiotic  use.
urthermore,  because  hematological  patients  often  present
ith  speciﬁc  pathophysiological  conditions  that  may  alter
he  pharmacokinetic  behavior  of  antimicrobials,  differing
dministration  schedules  and  antimicrobial  dosing  regimens
rom  the  standard  schedules  and  regimens  may  be  required.
peciﬁcally,  increased  doses  (e.g.,  aminoglycosides,  ﬂuoro-
uinolones),  prolonged  infusion  (e.g.,  beta-lactams),  and
herapeutic  drug  monitoring  are  important  to  optimize  the
ntimicrobial  use.  Pharmacokinetic  and  pharmacodynamic
rinciples  must  be  considered  when  designing  antimicrobial
egimens,  as  it  has  become  increasingly  clear  that  subopti-
al  concentrations  at  the  site  of  infection  may  contribute
o  increased  microbial  resistance.20
The  present  results  regarding  healthcare-associated
nfections  also  support  those  reported  by  previous  studies
n  children  with  cancer.21 The  rates  of  nosocomial  infec-
ions  and  antibiotic  resistance  are  much  higher  in  the  PICU
ompared  with  other  hospital  units.  Nosocomial  infections
ffect  up  to  30%  of  patients  in  the  ICU,  and  they  occur
ve  to  ten  times  more  often  than  in  non-ICU  patients.5
n  a  study  of  pediatric  patients  with  nosocomial  infection,
he  overall  incidence  of  nosocomial  infection  was  2.5%,
anging  from  1%  in  general  pediatric  units  to  23.6%  in  the
ICU.18 Several  factors  may  account  for  these  differences,
ncluding  the  use  of  more  invasive  procedures,  poor  hand
ygiene,  lapses  in  aseptic  techniques,  selective  pressure
or  antibiotics  due  to  inappropriate  use,  patient  transfers
ithin  the  hospital,  severe  underlying  disease,  malnutri-
ion,  and  immunosuppression.5 In  the  present  study,  the
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uration  were  associated  with  MDR  infection  in  the  uni-
ariate  analysis,  but  not  in  the  multivariate  analysis,  likely
wing  to  the  fact  that  these  variables  were  inter-related
ith  healthcare-associated  infections  or  hematologic  dis-
ases  that  were  strongly  associated  with  MDR-GNB  infection
n  the  multivariate  analysis.
Relationships  between  resistant  bacterial  infections  and
oor  outcomes  have  been  reported.5 One  determining  fac-
or  in  the  outcome  of  patients  with  infections  is  the  choice
f  appropriate  empirical  therapy  within  the  ﬁrst  48  h  of
he  initial  symptoms  and  within  the  ﬁrst  24  h  of  a  positive
lood  culture.4 In  the  current  study,  the  group  with  MDR-
NB  infections  received  inappropriate  empirical  antibiotic
herapy  more  frequently  than  the  group  without  MDR-GNB
nfections,  and  the  time  to  receive  adequate  therapy  was
onger  in  the  patients  with  MDR-GNB  infections.  There  was
lso  a  trend  for  greater  7-  and  30-day  mortality  in  the
atients  with  MDR-GNB;  however,  this  was  not  statistically
igniﬁcant.
A previous  study  in  pediatric  cancer  patients  also
eported  no  statistically  signiﬁcant  differences  in  infection-
elated  or  all-cause  mortality  due  to  MDR-GNB  infections.21
The  relationship  between  the  timeliness  of  adequate
herapy  and  prognosis  is  complex.  Physicians  tend  to
rescribe  early  extended-spectrum  antimicrobial  therapy
o  patients  with  severe  clinical  presentations.  In  con-
rast,  antimicrobial  therapy  is  often  delayed  in  patients
ho  do  not  present  with  organ  dysfunction  or  who  have
elayed  positivity  of  blood  cultures.  Finally,  patients  with
 rapid  progression  to  death  never  receive  antimicrobial
herapy.22
In  this  study,  the  median  time  to  initiate  adequate  antibi-
tic  therapy  was  2  days  in  children  with  MDR-GNB  infection,
ith  no  impact  on  mortality.  Studies  regarding  the  effect  of
 delay  to  initiate  adequate  antibiotics  on  mortality  in  pedi-
tric  patients  are  lacking.  However,  in  studies  with  adults,  a
elay  of  2--3  days  to  initiate  adequate  antibiotics  had  little
ffect  on  patient  mortality.23--26
The  strengths  of  the  current  study  include  the  popula-
ion,  which  had  a  combination  of  risk  factors  for  MDR-GNB
nfections:  cancer  and  an  ICU  stay.  Furthermore,  the  knowl-
dge  of  risk  factors  for  MDR-GNB  might  help  clinicians
dentify  patients  who  require  more  attention  during  the
mpirical  prescription  of  antimicrobial  therapy,  special
onitoring,  and  infection  control  measures.
This  study  had  certain  limitations,  including  the  collec-
ion  of  retrospective  data  in  a  small  sample.  Despite  this,
here  were  no  missing  data,  and  signiﬁcant  differences  were
bserved.
onclusion
ediatric  patients  with  hematological  cancer  can  expe-
ience  healthcare-associated  infection  suspected  to  be
ssociated  with  MDR-GNB.  This  reinforces  the  need  for
raining  about  the  transmission  risks  and  preventive  mea-
ures  for  health  professionals  (e.g.,  equipment  handling
echniques).  Contact  precautions  for  all  patients  with  colo-
ization  or  infection  with  MDR  pathogens  and  an  antibiotic
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